Chemotherapy for Cervical Cancer in India: Cisplatin, Bevacizumab, Pembrolizumab — and What They Actually Cost

Three drugs. Three completely different mechanisms. Cisplatin makes radiation lethal. Bevacizumab starves the tumour of blood supply. Pembrolizumab removes cancer's immune disguise. This guide explains what each drug does, which patients need which combination, and what the full drug cost looks like in India versus the US and UK — with landmark trial data cited at every step.

By Gaf Healthcare Editorial Team

2026-05-10

<!DOCTYPE html> <html lang="en"> <head> <meta charset="UTF-8"> <meta name="viewport" content="width=device-width, initial-scale=1.0"> <title>Chemotherapy for Cervical Cancer in India: Cisplatin, Bevacizumab, and What They Cost</title> <meta name="description" content="Cisplatin, bevacizumab, pembrolizumab — the drugs that treat cervical cancer explained. See the protocols India uses and what a full treatment course costs vs the US and UK."> <link rel="preconnect" href="https://fonts.googleapis.com"> <link href="https://fonts.googleapis.com/css2?family=Lora:ital,wght@0,400;0,600;1,400&family=Source+Sans+3:wght@400;500;600&display=swap" rel="stylesheet"> <style> , ::before, *::after { box-sizing: border-box; margin: 0; padding: 0; } :root { --cream: #F5F2EB; --cream-dark: #EDE9DF; --green-dark: #1B5E3B; --green-mid: #2D7A52; --green-light: #EAF4EE; --green-border: #C2DFCC; --red-accent: #B84040; --red-bg: #FDF2F2; --amber: #B07A15; --amber-bg: #FDF7EC; --amber-border: #E8D5A0; --blue: #2A5FA8; --blue-bg: #EEF4FB; --blue-border: #B8D0E8; --text-primary: #1A1A18; --text-body: #2E2E2A; --text-muted: #6B6860; --text-green: #1B5E3B; --border-soft: #DDD9CF; } body { font-family: 'Source Sans 3', sans-serif; background-color: var(--cream); color: var(--text-body); font-size: 18px; line-height: 1.75; -webkit-font-smoothing: antialiased; } .page-wrap { max-width: 740px; margin: 0 auto; padding: 48px 24px 80px; } .meta-tag { display: inline-block; font-size: 11px; font-weight: 600; letter-spacing: 0.12em; text-transform: uppercase; color: var(--text-green); background: var(--green-light); border: 1px solid var(--green-border); border-radius: 4px; padding: 3px 10px; margin-bottom: 18px; } h1 { font-family: 'Lora', Georgia, serif; font-size: clamp(26px, 4vw, 38px); font-weight: 600; line-height: 1.25; color: var(--text-primary); margin-bottom: 18px; letter-spacing: -0.01em; } .deck { font-size: 19px; line-height: 1.6; color: var(--text-muted); margin-bottom: 28px; border-bottom: 1px solid var(--border-soft); padding-bottom: 28px; }

/ ILLUSTRATION / .illustration-wrap { margin: 8px 0 36px; border-radius: 10px; overflow: hidden; border: 1px solid var(--border-soft); background: var(--cream-dark); } .illustration-wrap svg { display: block; width: 100%; } .img-caption { font-size: 13px; color: var(--text-muted); padding: 10px 16px 12px; border-top: 1px solid var(--border-soft); font-style: italic; line-height: 1.6; }

/ TOC / .toc-box { background: var(--cream-dark); border: 1px solid var(--border-soft); border-radius: 10px; padding: 20px 24px 24px; margin: 0 0 40px; } .toc-label { display: flex; align-items: center; gap: 8px; font-size: 11px; font-weight: 600; letter-spacing: 0.1em; text-transform: uppercase; color: var(--text-muted); margin-bottom: 14px; } .toc-label::before { content: ""; display: inline-block; width: 14px; height: 14px; background: var(--border-soft); border-radius: 2px; } .toc-box ol { list-style: none; padding: 0; display: flex; flex-direction: column; gap: 8px; } .toc-box ol li a { color: var(--text-green); text-decoration: none; font-size: 16px; font-weight: 500; border-bottom: 1px solid transparent; transition: border-color 0.15s; } .toc-box ol li a:hover { border-color: var(--green-mid); }

/ PROSE / .prose h2 { font-family: 'Lora', Georgia, serif; font-size: clamp(20px, 3vw, 26px); font-weight: 600; color: var(--text-primary); margin: 44px 0 6px; padding-bottom: 12px; border-bottom: 1px solid var(--border-soft); letter-spacing: -0.01em; } .prose p { font-family: 'Lora', Georgia, serif; font-size: 18px; line-height: 1.82; color: var(--text-body); margin-bottom: 16px; max-width: 68ch; } .prose p strong { font-weight: 600; color: var(--text-primary); } .prose p.impact { font-size: 19px; font-style: italic; color: var(--text-muted); border-left: 3px solid var(--green-mid); padding-left: 18px; margin: 24px 0; }

/ INLINE SOURCE / .source-inline { font-family: 'Source Sans 3', sans-serif; font-size: 12px; color: var(--text-muted); font-style: italic; margin: -8px 0 20px; line-height: 1.5; display: block; }

/ QUICK ANSWER / .quick-box { background: var(--green-light); border: 1.5px solid var(--green-border); border-radius: 10px; padding: 20px 24px 22px; margin: 20px 0 24px; } .quick-box .qa-label { font-size: 11px; font-weight: 600; letter-spacing: 0.1em; text-transform: uppercase; color: var(--amber); display: flex; align-items: center; gap: 6px; margin-bottom: 10px; } .quick-box .qa-label::before { content: "⚡"; font-size: 13px; } .quick-box .qa-question { font-family: 'Source Sans 3', sans-serif; font-weight: 600; font-size: 17px; color: var(--text-primary); margin-bottom: 10px; } .quick-box .qa-answer { font-family: 'Source Sans 3', sans-serif; font-size: 16px; line-height: 1.7; color: var(--text-body); } .quick-box .qa-answer strong { color: var(--text-primary); }

/ LANDMARK BOX / .landmark-box { background: var(--blue-bg); border: 1px solid var(--blue-border); border-radius: 10px; padding: 18px 22px 20px; margin: 20px 0 8px; } .landmark-box .lm-label { font-family: 'Source Sans 3', sans-serif; font-size: 10px; font-weight: 600; letter-spacing: 0.1em; text-transform: uppercase; color: var(--blue); margin-bottom: 8px; } .landmark-box .lm-question { font-family: 'Source Sans 3', sans-serif; font-weight: 600; font-size: 16px; color: var(--text-primary); margin-bottom: 8px; line-height: 1.4; } .landmark-box .lm-answer { font-family: 'Source Sans 3', sans-serif; font-size: 15px; line-height: 1.72; color: var(--text-body); } .landmark-box .lm-answer strong { color: var(--text-primary); font-weight: 600; }

/ DRUG CARDS / .drug-list { display: flex; flex-direction: column; gap: 20px; margin: 20px 0 8px; } .drug-card { border: 1px solid var(--border-soft); border-radius: 10px; overflow: hidden; } .drug-card-head { padding: 16px 20px 14px; border-bottom: 1px solid var(--border-soft); } .drug-card-head.dc-green { background: var(--green-light); } .drug-card-head.dc-amber { background: var(--amber-bg); } .drug-card-head.dc-blue { background: var(--blue-bg); } .drug-card-head .dc-label { font-family: 'Source Sans 3', sans-serif; font-size: 10px; font-weight: 600; letter-spacing: 0.1em; text-transform: uppercase; margin-bottom: 4px; } .dc-green .dc-label { color: var(--green-dark); } .dc-amber .dc-label { color: var(--amber); } .dc-blue .dc-label { color: var(--blue); } .drug-card-head h3 { font-family: 'Lora', Georgia, serif; font-size: 20px; font-weight: 600; color: var(--text-primary); line-height: 1.25; } .drug-card-head .dc-sub { font-family: 'Source Sans 3', sans-serif; font-size: 13px; color: var(--text-muted); margin-top: 3px; } .drug-card-body { padding: 16px 20px 18px; background: #fff; } .drug-card-body p { font-family: 'Source Sans 3', sans-serif; font-size: 15px; color: var(--text-body); line-height: 1.72; margin-bottom: 10px; max-width: none; } .drug-card-body p:last-child { margin-bottom: 0; } .drug-card-body p strong { color: var(--text-primary); font-weight: 600; } .drug-card-foot { display: grid; grid-template-columns: repeat(3, 1fr); border-top: 1px solid var(--border-soft); } .dc-foot-cell { padding: 12px 16px 14px; border-right: 1px solid var(--border-soft); } .dc-foot-cell:last-child { border-right: none; } .dc-foot-cell .fc-label { font-family: 'Source Sans 3', sans-serif; font-size: 10px; font-weight: 600; letter-spacing: 0.08em; text-transform: uppercase; color: var(--text-muted); margin-bottom: 4px; } .dc-foot-cell .fc-val { font-family: 'Source Sans 3', sans-serif; font-size: 15px; font-weight: 600; color: var(--green-mid); } .dc-foot-cell .fc-comp { font-family: 'Source Sans 3', sans-serif; font-size: 12px; color: var(--text-muted); margin-top: 2px; }

/ STAT STRIP / .stat-strip { display: grid; grid-template-columns: repeat(auto-fit, minmax(120px, 1fr)); border: 1px solid var(--border-soft); border-radius: 8px; overflow: hidden; margin: 18px 0 8px; } .stat-cell { padding: 14px 16px 16px; border-right: 1px solid var(--border-soft); } .stat-cell:last-child { border-right: none; } .stat-cell .stat-label { font-size: 10px; font-weight: 600; letter-spacing: 0.1em; text-transform: uppercase; color: var(--text-muted); margin-bottom: 5px; } .stat-cell .stat-val { font-size: 22px; font-weight: 600; color: var(--green-mid); font-family: 'Source Sans 3', sans-serif; line-height: 1.1; }

/ PROTOCOL SEQUENCE / .protocol-box { background: #fff; border: 1px solid var(--border-soft); border-radius: 10px; overflow: hidden; margin: 20px 0 8px; } .protocol-box h4 { font-family: 'Source Sans 3', sans-serif; font-size: 13px; font-weight: 600; letter-spacing: 0.08em; text-transform: uppercase; color: var(--text-muted); padding: 14px 18px 10px; border-bottom: 1px solid var(--border-soft); background: var(--cream-dark); } .protocol-row { display: flex; align-items: flex-start; gap: 14px; padding: 12px 18px 14px; border-bottom: 1px solid var(--border-soft); } .protocol-row:last-child { border-bottom: none; } .protocol-row .pr-phase { font-family: 'Source Sans 3', sans-serif; font-size: 11px; font-weight: 600; color: var(--text-green); background: var(--green-light); border: 1px solid var(--green-border); border-radius: 4px; padding: 3px 9px; flex-shrink: 0; white-space: nowrap; margin-top: 2px; } .protocol-row .pr-content { flex: 1; } .protocol-row .pr-content h5 { font-family: 'Source Sans 3', sans-serif; font-size: 15px; font-weight: 600; color: var(--text-primary); margin-bottom: 3px; } .protocol-row .pr-content p { font-family: 'Source Sans 3', sans-serif; font-size: 14px; color: var(--text-muted); line-height: 1.6; margin: 0; max-width: none; } .protocol-row .pr-content p strong { color: var(--text-primary); }

/ COST TABLE / .cost-table { width: 100%; border-collapse: collapse; border: 1px solid var(--border-soft); border-radius: 8px; overflow: hidden; margin: 18px 0 8px; font-size: 14px; } .cost-table thead th { background: var(--cream-dark); padding: 11px 13px; text-align: left; font-size: 10px; font-weight: 600; letter-spacing: 0.07em; text-transform: uppercase; color: var(--text-muted); border-bottom: 1px solid var(--border-soft); } .cost-table thead th.india-head { background: var(--green-light); color: var(--green-dark); } .cost-table tbody td { padding: 11px 13px; border-bottom: 1px solid var(--border-soft); font-family: 'Source Sans 3', sans-serif; color: var(--text-body); line-height: 1.5; vertical-align: top; } .cost-table tbody tr:last-child td { border-bottom: none; } .cost-table tbody td:first-child { font-weight: 600; color: var(--text-primary); width: 32%; } .cost-table .highlight td { background: #FAFAF7; } .cost-table .saving { color: var(--green-mid); font-weight: 600; } .cost-table .saving-pct { display: inline-block; font-size: 11px; font-weight: 600; background: var(--green-light); color: var(--green-dark); border-radius: 4px; padding: 1px 6px; margin-left: 4px; }

/ CALLOUTS / .callout-green { border-left: 3px solid var(--green-mid); background: var(--green-light); border-radius: 0 8px 8px 0; padding: 16px 20px 18px; margin: 20px 0; } .callout-green .callout-label { font-size: 11px; font-weight: 600; letter-spacing: 0.1em; text-transform: uppercase; color: var(--text-green); margin-bottom: 8px; } .callout-red { border-left: 3px solid var(--red-accent); background: var(--red-bg); border-radius: 0 8px 8px 0; padding: 16px 20px 18px; margin: 20px 0; } .callout-red .callout-label { font-size: 11px; font-weight: 600; letter-spacing: 0.1em; text-transform: uppercase; color: var(--red-accent); margin-bottom: 8px; } .callout-amber { border-left: 3px solid var(--amber); background: var(--amber-bg); border-radius: 0 8px 8px 0; padding: 16px 20px 18px; margin: 20px 0; } .callout-amber .callout-label { font-size: 11px; font-weight: 600; letter-spacing: 0.1em; text-transform: uppercase; color: var(--amber); margin-bottom: 8px; } .callout-green p, .callout-red p, .callout-amber p { font-size: 16px; line-height: 1.7; font-family: 'Source Sans 3', sans-serif; color: var(--text-body); margin: 0; max-width: none; }

/ CTAs / .cta-a { background: var(--green-dark); border-radius: 12px; padding: 28px 28px 30px; margin: 32px 0; } .cta-a .cta-h { font-family: 'Source Sans 3', sans-serif; font-size: 18px; font-weight: 600; color: #fff; margin-bottom: 8px; line-height: 1.4; } .cta-a .cta-s { font-family: 'Source Sans 3', sans-serif; font-size: 15px; color: rgba(255,255,255,.78); margin-bottom: 20px; line-height: 1.6; } .btn-white { display: inline-block; background: #fff; color: var(--green-dark); font-family: 'Source Sans 3', sans-serif; font-size: 15px; font-weight: 600; padding: 11px 22px; border-radius: 6px; text-decoration: none; transition: background 0.15s; } .btn-white:hover { background: #e8f4ee; } .cta-b { border: 1.5px solid var(--green-border); background: #fff; border-radius: 10px; padding: 20px 22px 22px; margin: 24px 0; display: flex; flex-direction: column; gap: 10px; } .cta-b .cta-h { font-family: 'Source Sans 3', sans-serif; font-size: 16px; font-weight: 600; color: var(--text-primary); line-height: 1.4; } .cta-b .cta-s { font-family: 'Source Sans 3', sans-serif; font-size: 14px; color: var(--text-muted); line-height: 1.6; } .btn-green { display: inline-block; background: var(--green-dark); color: #fff; font-family: 'Source Sans 3', sans-serif; font-size: 14px; font-weight: 600; padding: 10px 20px; border-radius: 6px; text-decoration: none; align-self: flex-start; transition: background 0.15s; } .btn-green:hover { background: var(--green-mid); } .cta-c { display: flex; align-items: flex-start; gap: 14px; background: var(--cream-dark); border: 1px solid var(--border-soft); border-radius: 8px; padding: 16px 20px; margin: 20px 0; text-decoration: none; transition: border-color 0.15s, background 0.15s; } .cta-c:hover { background: var(--green-light); border-color: var(--green-border); } .cta-c .cta-arrow { font-size: 20px; color: var(--green-mid); line-height: 1; flex-shrink: 0; margin-top: 2px; } .cta-c .rl-label { font-size: 15px; color: var(--green-mid); font-weight: 600; margin-bottom: 4px; font-family: 'Source Sans 3', sans-serif; } .cta-c .rl-desc { font-size: 14px; color: var(--text-muted); font-family: 'Source Sans 3', sans-serif; line-height: 1.5; }

@media (max-width: 600px) { .stat-strip { grid-template-columns: 1fr 1fr; } .cost-table { font-size: 13px; } .cost-table thead th, .cost-table tbody td { padding: 9px 10px; } .drug-card-foot { grid-template-columns: 1fr; } .dc-foot-cell { border-right: none; border-bottom: 1px solid var(--border-soft); } .dc-foot-cell:last-child { border-bottom: none; } } </style> </head> <body> <div class="page-wrap">

<span class="meta-tag">Cervical Cancer · Chemotherapy · India</span>

<h1>Chemotherapy for Cervical Cancer in India: Cisplatin, Bevacizumab, Pembrolizumab — and What They Actually Cost</h1>

<p class="deck">Three very different drugs. Three very different roles. Cisplatin makes radiation more powerful. Bevacizumab cuts off the tumour's blood supply. Pembrolizumab teaches the immune system to attack the cancer. Understanding which drug does what — and why the cost difference between India and the West is so dramatic — puts you in a far stronger position to make the right decisions.</p>

<div class="illustration-wrap"> <svg viewBox="0 0 700 200" xmlns="http://www.w3.org/2000/svg" role="img" aria-label="Three-panel diagram showing the mechanism of action of the three main drugs used in cervical cancer treatment. The left panel shows cisplatin — a small molecule entering a cancer cell and binding to its DNA, forming cross-links that prevent DNA replication and make the cell more sensitive to radiation damage. The cell is labelled as radiosensitised. The middle panel shows bevacizumab — a large Y-shaped antibody molecule binding to VEGF, a growth factor released by tumour cells to stimulate new blood vessel formation. The antibody-VEGF complex is shown blocking a nearby blood vessel from sprouting, labelled as anti-angiogenesis. The right panel shows pembrolizumab — a Y-shaped antibody binding to PD-1 receptors on a T-cell, blocking the PD-1 and PD-L1 interaction that cancer cells use to switch off immune attack. The T-cell is shown becoming active and attacking a nearby cancer cell, labelled as immune checkpoint blockade. Each panel is colour-coded: green for cisplatin, amber for bevacizumab, and blue for pembrolizumab."> <defs> <linearGradient id="bgChemo" x1="0" y1="0" x2="0" y2="1"> <stop offset="0%" stop-color="#EDE9DF"/><stop offset="100%" stop-color="#E4DFCF"/> </linearGradient> </defs> <rect width="700" height="200" fill="url(#bgChemo)"/>

<text x="117" y="20" text-anchor="middle" font-family="'Source Sans 3',sans-serif" font-size="11" font-weight="600" fill="#1B5E3B" letter-spacing="0.06em">CISPLATIN</text> <text x="350" y="20" text-anchor="middle" font-family="'Source Sans 3',sans-serif" font-size="11" font-weight="600" fill="#8A5F10" letter-spacing="0.06em">BEVACIZUMAB</text> <text x="583" y="20" text-anchor="middle" font-family="'Source Sans 3',sans-serif" font-size="11" font-weight="600" fill="#2A5FA8" letter-spacing="0.06em">PEMBROLIZUMAB</text> <line x1="233" y1="12" x2="233" y2="188" stroke="#DDD9CF" stroke-width="1" stroke-dasharray="4 3"/> <line x1="467" y1="12" x2="467" y2="188" stroke="#DDD9CF" stroke-width="1" stroke-dasharray="4 3"/>

<ellipse cx="117" cy="105" rx="70" ry="60" fill="#F0EDE4" stroke="#C8C4BA" stroke-width="1.5"/> <ellipse cx="117" cy="112" rx="30" ry="26" fill="#FDE8D8" stroke="#D07040" stroke-width="1"/> <text x="117" y="116" text-anchor="middle" font-family="'Source Sans 3',sans-serif" font-size="9" fill="#A05020">nucleus</text>  <path d="M100 88 Q110 95 100 102 Q90 109 100 116" fill="none" stroke="#2D7A52" stroke-width="2" stroke-linecap="round"/> <path d="M134 88 Q124 95 134 102 Q144 109 134 116" fill="none" stroke="#2D7A52" stroke-width="2" stroke-linecap="round"/> <line x1="100" y1="92" x2="134" y2="92" stroke="#C2DFCC" stroke-width="1.2"/> <line x1="100" y1="102" x2="134" y2="102" stroke="#C2DFCC" stroke-width="1.2"/> <line x1="100" y1="112" x2="134" y2="112" stroke="#C2DFCC" stroke-width="1.2"/>  <circle cx="65" cy="90" r="8" fill="#2D7A52" opacity="0.85"/> <text x="65" y="94" text-anchor="middle" font-family="'Source Sans 3',sans-serif" font-size="8" fill="#fff" font-weight="700">Pt</text> <line x1="73" y1="92" x2="95" y2="100" stroke="#2D7A52" stroke-width="1.5" stroke-dasharray="3 2"/> <text x="117" y="168" text-anchor="middle" font-family="'Source Sans 3',sans-serif" font-size="10" fill="#1B5E3B" font-weight="600">Radiosensitiser</text> <text x="117" y="182" text-anchor="middle" font-family="'Source Sans 3',sans-serif" font-size="10" fill="#6B6860">40 mg/m² weekly during EBRT</text>

<circle cx="305" cy="82" r="14" fill="#FDE8D8" stroke="#D07040" stroke-width="1" opacity="0.8"/> <text x="305" y="86" text-anchor="middle" font-family="'Source Sans 3',sans-serif" font-size="8" fill="#A05020">VEGF</text>  <line x1="350" y1="60" x2="350" y2="85" stroke="#B07A15" stroke-width="3" stroke-linecap="round"/> <line x1="350" y1="85" x2="328" y2="105" stroke="#B07A15" stroke-width="2.5" stroke-linecap="round"/> <line x1="350" y1="85" x2="372" y2="105" stroke="#B07A15" stroke-width="2.5" stroke-linecap="round"/> <circle cx="350" cy="58" r="6" fill="#B07A15" opacity="0.7"/> <circle cx="326" cy="107" r="6" fill="#B07A15" opacity="0.7"/> <circle cx="374" cy="107" r="6" fill="#B07A15" opacity="0.7"/>  <line x1="326" y1="107" x2="310" y2="90" stroke="#B07A15" stroke-width="1.5" stroke-dasharray="3 2" opacity="0.7"/>  <rect x="380" y="115" width="70" height="22" rx="8" fill="#F0EDE4" stroke="#C8C4BA" stroke-width="1.5"/> <text x="415" y="130" text-anchor="middle" font-family="'Source Sans 3',sans-serif" font-size="9" fill="#9A4020">vessel growth blocked ✕</text> <text x="350" y="168" text-anchor="middle" font-family="'Source Sans 3',sans-serif" font-size="10" fill="#8A5F10" font-weight="600">Anti-angiogenic</text> <text x="350" y="182" text-anchor="middle" font-family="'Source Sans 3',sans-serif" font-size="10" fill="#6B6860">Blocks tumour blood supply</text>

<circle cx="545" cy="95" r="28" fill="#EEF4FB" stroke="#B8D0E8" stroke-width="1.5"/> <text x="545" y="99" text-anchor="middle" font-family="'Source Sans 3',sans-serif" font-size="10" fill="#2A5FA8" font-weight="600">T-cell</text>  <rect x="555" y="70" width="10" height="18" rx="3" fill="#2A5FA8" opacity="0.7"/>  <line x1="610" y1="60" x2="610" y2="78" stroke="#2A5FA8" stroke-width="2.5" stroke-linecap="round"/> <line x1="610" y1="78" x2="592" y2="92" stroke="#2A5FA8" stroke-width="2" stroke-linecap="round"/> <line x1="610" y1="78" x2="628" y2="92" stroke="#2A5FA8" stroke-width="2" stroke-linecap="round"/> <circle cx="610" cy="58" r="5" fill="#2A5FA8" opacity="0.7"/> <circle cx="590" cy="94" r="5" fill="#2A5FA8" opacity="0.7"/> <circle cx="630" cy="94" r="5" fill="#2A5FA8" opacity="0.7"/> <line x1="590" y1="92" x2="567" y2="80" stroke="#2A5FA8" stroke-width="1.5" stroke-dasharray="3 2" opacity="0.7"/>  <circle cx="615" cy="140" r="18" fill="#FDF2F2" stroke="#E8BABA" stroke-width="1.5"/> <text x="615" y="144" text-anchor="middle" font-family="'Source Sans 3',sans-serif" font-size="8" fill="#B84040">cancer</text> <line x1="565" y1="112" x2="600" y2="130" stroke="#2A5FA8" stroke-width="1.5" marker-end="url(#arB)"/> <defs><marker id="arB" viewBox="0 0 8 8" refX="6" refY="4" markerWidth="4" markerHeight="4" orient="auto"><path d="M1 1L7 4L1 7" fill="none" stroke="#2A5FA8" stroke-width="1.5" stroke-linecap="round"/></marker></defs> <text x="583" y="168" text-anchor="middle" font-family="'Source Sans 3',sans-serif" font-size="10" fill="#2A5FA8" font-weight="600">Immune checkpoint blockade</text> <text x="583" y="182" text-anchor="middle" font-family="'Source Sans 3',sans-serif" font-size="10" fill="#6B6860">Releases immune attack on cancer</text> </svg> <p class="img-caption">The three main drug classes used in cervical cancer treatment — and how they work. Cisplatin (left) enters cancer cells and damages DNA, making cells more sensitive to radiation — it is a radiosensitiser, not primary chemotherapy. Bevacizumab (centre) blocks VEGF, the growth factor cancer cells use to stimulate new blood vessel formation, cutting off the tumour's nutrient supply. Pembrolizumab (right) blocks the PD-1 checkpoint that cancer cells use to hide from the immune system, reactivating T-cells to attack the tumour. All three are available at India's partner hospitals at 80–94% lower cost than in the United States.</p> </div>

<div class="toc-box"> <div class="toc-label">What's in this guide</div> <ol> <li><a href="#three-roles">Three drugs, three roles — understanding the difference</a></li> <li><a href="#cisplatin">Cisplatin — the radiosensitiser that changed cervical cancer outcomes</a></li> <li><a href="#bevacizumab">Bevacizumab — the drug that added survival in advanced disease</a></li> <li><a href="#pembrolizumab">Pembrolizumab — the immunotherapy that has changed the landscape</a></li> <li><a href="#protocols">How the drugs are combined — treatment protocols by stage</a></li> <li><a href="#biosimilars">Bevacizumab biosimilars in India — the same drug at a fraction of the cost</a></li> <li><a href="#cost">What these drugs cost in India vs the US and UK</a></li> <li><a href="#access">Why access matters — and why India solves it</a></li> </ol> </div>

<h2 id="three-roles">Three drugs, three roles — understanding the difference</h2>

<p>When a patient with cervical cancer is told she needs "chemotherapy," that word covers three very different interventions that work through completely different mechanisms and are used at different stages of the disease.</p>

<p>Confusing them leads to confused conversations with oncologists — and sometimes to accepting inadequate treatment because a patient did not know to ask for something specific.</p>

<p><strong>Cisplatin</strong> is not primarily used to kill cancer cells in cervical cancer. It is used to make radiation more lethal to those cells. It is a radiosensitiser — a drug that amplifies the effect of each radiation fraction rather than acting on its own. Without it, radiation is significantly less effective. With it, local control rates increase substantially.</p>

<p><strong>Bevacizumab</strong> targets the blood supply the tumour is building for itself. Cancer cells secrete a growth factor called VEGF to stimulate new blood vessel formation — angiogenesis. Without new vessels, the tumour cannot grow. Bevacizumab is an antibody that binds VEGF and stops it from triggering that vessel growth.</p>

<p><strong>Pembrolizumab</strong> does something fundamentally different from the other two. It targets the immune system rather than the cancer cell directly. Cancer cells express a protein called PD-L1 that binds to PD-1 receptors on immune T-cells — essentially telling them "don't attack me." Pembrolizumab blocks this interaction, removing the cancer cell's disguise and allowing the immune system to attack it.</p>

<span class="source-inline">Sources: Begg AC, "Cisplatin and radiation: interaction probabilities and therapeutic possibilities," IJROBP, 1990 · Ferrara N, "VEGF and the quest for tumour angiogenesis factors," Nature Reviews Cancer, 2002 · Pardoll DM, "The blockade of immune checkpoints in cancer immunotherapy," Nature Reviews Cancer, 2012</span>

<div class="quick-box"> <div class="qa-label">Quick answer</div> <div class="qa-question">Do all cervical cancer patients need all three drugs?</div> <div class="qa-answer">No. <strong>Cisplatin</strong> is given to most patients with stage IB2 and above who are undergoing concurrent chemoradiation. <strong>Bevacizumab</strong> is added for persistent, recurrent, or metastatic disease — stage IV or cancer that has returned. <strong>Pembrolizumab</strong> is used for PD-L1-positive persistent, recurrent, or metastatic cervical cancer — as first-line therapy combined with chemotherapy, or as second-line after progression. Which drugs you receive depends on your stage, PD-L1 status, and how your cancer has responded to initial treatment.</div> </div>

<h2 id="cisplatin">Cisplatin — the radiosensitiser that changed cervical cancer outcomes</h2>

<p>Cisplatin is platinum-based. It has been in clinical use for over 50 years. And despite the arrival of far more sophisticated drugs, it remains the backbone of concurrent chemoradiation for locally advanced cervical cancer — because nothing has been shown to improve on it in this specific role.</p>

<p>The way it works as a radiosensitiser is mechanistically elegant. Cisplatin enters cancer cells and binds to their DNA, forming platinum-DNA adducts — crosslinks that physically distort the DNA double helix. These adducts prevent the cancer cell from repairing the DNA damage caused by radiation. When the radiation fraction delivers its dose, the cell cannot fix itself between fractions. The cumulative damage becomes lethal faster than it would without the platinum.</p>

<span class="source-inline">Source: Chabner BA, Longo DL, "Cancer Chemotherapy and Biotherapy: Principles and Practice," 5th Ed., Wolters Kluwer, 2011 · Begg AC, "Cisplatin and radiation: interaction probabilities and therapeutic possibilities," IJROBP, 1990</span>

<div class="drug-card"> <div class="drug-card-head dc-green"> <div class="dc-label">Concurrent chemoradiation · Stages IB2–IVA</div> <h3>Cisplatin</h3> <div class="dc-sub">Platinum-based radiosensitiser — the backbone of concurrent chemoradiation</div> </div> <div class="drug-card-body"> <p><strong>How it is given:</strong> Intravenous infusion once per week during external beam radiation, at a dose of 40 mg/m² of body surface area. A typical course is five to six weekly infusions running alongside the five to six week EBRT course. Each infusion takes approximately one to two hours in the outpatient day infusion unit.</p> <p><strong>Pre-hydration:</strong> Cisplatin is nephrotoxic — it can damage the kidneys. Every cisplatin infusion is preceded by intravenous fluid loading to protect renal function. Blood tests checking kidney function, blood counts, and electrolytes are done before each weekly dose.</p> <p><strong>When it is held:</strong> If kidney function deteriorates, blood counts fall below a safety threshold, or the patient has a significant infection, the weekly cisplatin dose may be held or reduced. This does not mean the radiation stops — EBRT continues on its daily schedule regardless of the cisplatin status.</p> <p><strong>In India:</strong> Cisplatin has been off-patent for decades. In India, the drug itself costs $30–$80 per weekly dose — the same molecule used at every cancer centre in the world. The weekly blood tests and oncology monitoring consultations cost $15–$40 per visit in India, versus $200–$800 per visit in the United States. Over a six-week course, the total cisplatin drug and monitoring cost in India is $300–$800, compared to $3,000–$9,000 in the US.</p> </div> <div class="drug-card-foot"> <div class="dc-foot-cell"> <div class="fc-label">India cost (per dose)</div> <div class="fc-val">$30–$80</div> <div class="fc-comp">vs $400–$1,200 USA</div> </div> <div class="dc-foot-cell"> <div class="fc-label">Full 6-week course (India)</div> <div class="fc-val">$180–$480</div> <div class="fc-comp">vs $2,400–$7,200 USA</div> </div> <div class="dc-foot-cell"> <div class="fc-label">Schedule</div> <div class="fc-val">Weekly</div> <div class="fc-comp">40 mg/m² IV during EBRT</div> </div> </div> </div>

<div class="landmark-box"> <div class="lm-label">📋 Landmark Evidence — Green JA et al., The Lancet 2001</div> <div class="lm-question">How much does cisplatin actually improve survival when added to radiation?</div> <div class="lm-answer">A meta-analysis of five randomised controlled trials — 1,774 patients — found that concurrent cisplatin-based chemoradiation reduced the risk of death by <strong>30% compared to radiation alone</strong> (hazard ratio 0.71, p=0.002). The absolute improvement in five-year overall survival was approximately 6 percentage points. A subsequent Cochrane review including 13 trials confirmed these findings and found consistent benefit across all stages. This evidence base is what established weekly cisplatin as the international standard — and the standard India's partner hospitals follow without exception.</div> </div> <span class="source-inline">Sources: Green JA et al., "Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix," The Lancet, 2001 · Vale C et al., Cochrane Collaboration systematic review of chemoradiation for cervical cancer, 2010</span>

<div class="cta-b"> <p class="cta-h">Starting concurrent chemoradiation and want to understand the full treatment plan?</p> <p class="cta-s">Share your stage and diagnosis. Our India-based coordinators will outline exactly what cisplatin weeks involve, what monitoring you will need, and what the full treatment costs — at no charge, within 24 hours.</p> <a href="https://gafhealthcare.in/contact" class="btn-green">Get a Free Treatment Walkthrough →</a> </div>

<h2 id="bevacizumab">Bevacizumab — the drug that added survival in advanced disease</h2>

<p>Bevacizumab was the first targeted drug to demonstrate a meaningful survival benefit in recurrent or metastatic cervical cancer. Its approval was significant not just because of what it achieved, but because of how long it had taken to find anything that improved on platinum-based chemotherapy alone in this patient group.</p>

<p>Cervical cancer tumours are highly angiogenic — they produce large amounts of VEGF to build the new blood vessels they need to grow and spread. Bevacizumab is a monoclonal antibody that binds directly to VEGF and neutralises it before it can stimulate vessel formation. The tumour's blood supply is starved. Growth slows. And when combined with chemotherapy, the effect on tumour control is significantly better than chemotherapy alone.</p>

<span class="source-inline">Source: Ferrara N, Hillan KJ, Gerber HP, Novotny W, "Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer," Nature Reviews Drug Discovery, 2004</span>

<div class="drug-card"> <div class="drug-card-head dc-amber"> <div class="dc-label">Recurrent / Metastatic / Persistent disease · Stage IVB</div> <h3>Bevacizumab (Avastin / biosimilar)</h3> <div class="dc-sub">Anti-VEGF antibody — added to platinum-based chemotherapy for advanced disease</div> </div> <div class="drug-card-body"> <p><strong>How it is given:</strong> Intravenous infusion every three weeks, combined with carboplatin and paclitaxel (or cisplatin and paclitaxel). Each infusion cycle includes all three drugs. Bevacizumab continues until disease progression or unacceptable toxicity.</p> <p><strong>Key side effects to know about:</strong> Bevacizumab carries specific risks that differ from conventional chemotherapy. The most important are hypertension (blood pressure monitoring at every cycle), impaired wound healing (it must be stopped before any planned surgery and for four to six weeks after), and — rarely but seriously — gastrointestinal perforation and fistula formation. Patients with a history of fistula from previous radiation are assessed carefully before bevacizumab is started.</p> <p><strong>The biosimilar story in India:</strong> The branded bevacizumab (Avastin) costs $4,000–$8,000 per cycle in the United States. In India, bevacizumab biosimilars — approved by India's Central Drugs Standard Control Organisation and demonstrated to be clinically equivalent to the original — are available at <strong>$200–$500 per cycle</strong>. For patients from countries where bevacizumab is unaffordable or unavailable, India represents access to a survival-prolonging drug at a realistic price.</p> <p><strong>Who qualifies:</strong> Bevacizumab is approved for persistent, recurrent, or metastatic cervical cancer regardless of PD-L1 status. It is given in combination with platinum-based chemotherapy, not as monotherapy.</p> </div> <div class="drug-card-foot"> <div class="dc-foot-cell"> <div class="fc-label">India cost (per cycle)</div> <div class="fc-val">$200–$500</div> <div class="fc-comp">vs $4,000–$8,000 USA</div> </div> <div class="dc-foot-cell"> <div class="fc-label">Saving vs USA</div> <div class="fc-val">~94%</div> <div class="fc-comp">same molecule, biosimilar</div> </div> <div class="dc-foot-cell"> <div class="fc-label">Schedule</div> <div class="fc-val">Every 3 weeks</div> <div class="fc-comp">With carbo/paclitaxel</div> </div> </div> </div>

<div class="landmark-box"> <div class="lm-label">📋 Landmark Evidence — GOG-240 Trial, NEJM 2014</div> <div class="lm-question">How much does bevacizumab improve survival in advanced cervical cancer?</div> <div class="lm-answer">The GOG-240 trial — a randomised phase III study comparing chemotherapy alone versus chemotherapy plus bevacizumab in 452 patients with recurrent, persistent, or metastatic cervical cancer — found that adding bevacizumab improved <strong>median overall survival from 13.3 months to 17.0 months</strong> — a 3.7-month gain (hazard ratio 0.71, p=0.004). Response rate improved from 36% to 48%. This was the first trial to show a survival benefit from any targeted agent in cervical cancer. The combination of carboplatin, paclitaxel, and bevacizumab is now the internationally recommended first-line regimen for recurrent or metastatic disease in patients without a contraindication.</div> </div> <span class="source-inline">Source: Tewari KS et al., "Improved survival with bevacizumab in advanced cervical cancer" (GOG-240), New England Journal of Medicine, 2014</span>

<h2 id="pembrolizumab">Pembrolizumab — the immunotherapy that has changed the landscape</h2>

<p>Pembrolizumab does not work like any drug that came before it in cervical cancer treatment. It does not attack the cancer cell directly. It removes a disguise.</p>

<p>Cancer cells in cervical cancer — like many cancers — express PD-L1, a protein that binds to PD-1 receptors on immune system T-cells. When PD-L1 binds PD-1, it sends a "don't attack" signal. The T-cell stands down. The cancer cell goes unchallenged by the immune system that should be destroying it.</p>

<p>Pembrolizumab is a monoclonal antibody that blocks PD-1 on the T-cell surface. When PD-1 is blocked, the cancer cell's disguise no longer works. The T-cells recognise the cancer and attack it.</p>

<span class="source-inline">Source: Topalian SL et al., "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer," New England Journal of Medicine, 2012 · Brahmer JR et al., "Safety and activity of anti-PD-L1 antibody in patients with advanced cancer," NEJM, 2012</span>

<div class="drug-card"> <div class="drug-card-head dc-blue"> <div class="dc-label">Persistent / Recurrent / Metastatic · PD-L1 positive</div> <h3>Pembrolizumab (Keytruda)</h3> <div class="dc-sub">PD-1 immune checkpoint inhibitor — first-line combination or second-line monotherapy</div> </div> <div class="drug-card-body"> <p><strong>Who qualifies:</strong> Pembrolizumab is approved for patients with persistent, recurrent, or metastatic cervical cancer whose tumours express PD-L1 — tested by immunohistochemistry on the tumour tissue sample. The combined positive score (CPS) ≥1 is the threshold for first-line combination use. PD-L1 testing is performed as part of the biomarker workup at India's partner hospitals before systemic treatment begins for advanced disease.</p> <p><strong>How it is given:</strong> Intravenous infusion every three or six weeks. In first-line combination therapy, pembrolizumab is given together with carboplatin and paclitaxel, with or without bevacizumab, for up to 35 cycles (approximately two years). As second-line monotherapy, it is continued until disease progression or unacceptable toxicity.</p> <p><strong>Immune-related side effects:</strong> Pembrolizumab carries a distinct side-effect profile from chemotherapy — not nausea and hair loss, but immune-related reactions. The immune system, once unblocked, can attack healthy tissues too — most commonly the thyroid, lungs, liver, and colon. These reactions are manageable with corticosteroids in most cases but require prompt identification. India's oncology teams at all four partner hospitals are experienced in immune-related adverse event management.</p> <p><strong>Cost in India:</strong> Pembrolizumab costs $10,000–$14,000 per cycle in the United States. In India, it is available at <strong>$1,200–$2,200 per cycle</strong> — still a meaningful cost, but within the range of realistic family planning for most patients from Africa, South Asia, and the Gulf. For patients whose PD-L1-positive tumour would benefit from pembrolizumab but who cannot afford US or UK prices, India is the access point.</p> </div> <div class="drug-card-foot"> <div class="dc-foot-cell"> <div class="fc-label">India cost (per cycle)</div> <div class="fc-val">$1,200–$2,200</div> <div class="fc-comp">vs $10,000–$14,000 USA</div> </div> <div class="dc-foot-cell"> <div class="fc-label">Saving vs USA</div> <div class="fc-val">~88%</div> <div class="fc-comp">same branded drug</div> </div> <div class="dc-foot-cell"> <div class="fc-label">Schedule</div> <div class="fc-val">Q3W or Q6W</div> <div class="fc-comp">Up to 35 cycles</div> </div> </div> </div>

<div class="landmark-box"> <div class="lm-label">📋 Landmark Evidence — KEYNOTE-826 Trial, NEJM 2022</div> <div class="lm-question">What does adding pembrolizumab to first-line chemotherapy achieve in advanced cervical cancer?</div> <div class="lm-answer">The KEYNOTE-826 trial — 617 patients with persistent, recurrent, or metastatic cervical cancer who had not received prior chemotherapy — randomised patients to carboplatin/paclitaxel ± bevacizumab, with or without pembrolizumab. In patients with CPS ≥1 (approximately 88% of the population), pembrolizumab addition reduced the risk of death by <strong>36%</strong> (hazard ratio 0.64, p<0.001). Median progression-free survival improved from 8.2 to 10.4 months. The 24-month overall survival rate was 53% with pembrolizumab versus 41.7% without. These results led to FDA and EMA approval of pembrolizumab in this setting, and it is now the international standard first-line regimen for PD-L1-positive advanced cervical cancer.</div> </div> <span class="source-inline">Source: Colombo N et al., "Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer" (KEYNOTE-826), New England Journal of Medicine, 2022</span>

<div class="cta-a"> <p class="cta-h">Advanced cervical cancer — need pembrolizumab or bevacizumab but cannot afford Western prices?</p> <p class="cta-s">Both drugs are available in India at 88–94% lower cost than the US. Share your diagnosis, PD-L1 status if known, and existing treatment history. Our team will outline your options and calculate the full drug cost for your specific regimen — at no charge, within 24 hours.</p> <a href="https://gafhealthcare.in/contact" class="btn-white">Get My Drug Cost Estimate →</a> </div>

<h2 id="protocols">How the drugs are combined — treatment protocols by stage</h2>

<p>Understanding which drug combination applies to your stage and situation removes ambiguity from conversations with your oncologist — and helps you ask the right questions about whether India's formulary covers exactly what you need.</p>

<div class="protocol-box"> <h4>Cervical cancer systemic therapy — by stage and situation</h4> <div class="protocol-row"> <div class="pr-phase">Stage IB2–IVA</div> <div class="pr-content"> <h5>Concurrent chemoradiation — cisplatin + EBRT + brachytherapy</h5> <p>Weekly cisplatin 40 mg/m² IV during 5–6 weeks of external beam radiation, followed by brachytherapy. <strong>No bevacizumab or pembrolizumab at this stage</strong> — the immunotherapy role in concurrent chemoradiation is under investigation (KEYNOTE-A18 trial) but not yet standard outside clinical trials.</p> </div> </div> <div class="protocol-row"> <div class="pr-phase">Stage IVB (1st line)</div> <div class="pr-content"> <h5>Carboplatin + paclitaxel + bevacizumab + pembrolizumab (CPS ≥1)</h5> <p>The current international standard for PD-L1-positive recurrent or metastatic disease following the KEYNOTE-826 trial. Pembrolizumab every three or six weeks for up to 35 cycles; chemotherapy continued for six cycles; bevacizumab continued until progression. <strong>All four drugs available in India</strong> at 80–94% lower cost than in the US.</p> </div> </div> <div class="protocol-row"> <div class="pr-phase">Stage IVB (1st line, PD-L1 negative)</div> <div class="pr-content"> <h5>Carboplatin + paclitaxel + bevacizumab</h5> <p>For patients with CPS <1 or in centres where PD-L1 testing is not yet available, carboplatin/paclitaxel plus bevacizumab remains the recommended standard based on GOG-240. <strong>Bevacizumab biosimilar in India: $200–$500 per cycle</strong>.</p> </div> </div> <div class="protocol-row"> <div class="pr-phase">Recurrent (2nd line)</div> <div class="pr-content"> <h5>Pembrolizumab monotherapy (CPS ≥1, prior platinum)</h5> <p>For patients who progressed on or after platinum-based chemotherapy and whose tumour expresses PD-L1. Pembrolizumab monotherapy at 200 mg every three weeks or 400 mg every six weeks until progression. Response rates of approximately 14% in unselected patients and higher in CPS-high tumours. <strong>Available at all four GAF Healthcare partner hospitals in India</strong>.</p> </div> </div> <div class="protocol-row"> <div class="pr-phase">Adjuvant</div> <div class="pr-content"> <h5>KEYNOTE-A18: pembrolizumab + concurrent chemoradiation (trial standard)</h5> <p>The KEYNOTE-A18 trial established that adding pembrolizumab to concurrent chemoradiation in stage IIB–IVA cervical cancer improved progression-free survival — the first trial to show benefit in this setting. <strong>This combination is now available as an option at Tata Memorial and Apollo</strong> for eligible patients with locally advanced disease.</p> </div> </div> </div> <span class="source-inline">Sources: NCCN Clinical Practice Guidelines — Cervical Cancer v1.2025 · Lorusso D et al., "Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer" (KEYNOTE-A18), The Lancet, 2024 · Colombo N et al., KEYNOTE-826, NEJM, 2022</span>

<h2 id="biosimilars">Bevacizumab biosimilars in India — the same drug at a fraction of the cost</h2>

<p>The word "biosimilar" deserves an honest explanation — because patients hear it and sometimes worry it means a weaker or less safe version of the original drug. It does not.</p>

<p>A biosimilar is a biological drug that has been demonstrated to be highly similar to an approved reference product — in this case, the original bevacizumab (Avastin). The manufacturer must prove, through comprehensive analytical, preclinical, and clinical studies, that there are no clinically meaningful differences in safety, purity, or potency between the biosimilar and the reference drug.</p>

<span class="source-inline">Source: US Food and Drug Administration, "Biosimilars: Questions and Answers," FDA Guidance Document, 2015 · European Medicines Agency, "Guideline on similar biological medicinal products," EMA/CHMP/BWP, 2014</span>

<p>India's Central Drugs Standard Control Organisation (CDSCO) applies regulatory standards aligned with WHO biosimilar guidelines. Bevacizumab biosimilars approved in India have undergone pharmacokinetic equivalence studies, immunogenicity assessment, and safety monitoring consistent with international biosimilar development standards.</p>

<span class="source-inline">Source: WHO Expert Committee on Biological Standardization, "Guidelines on evaluation of similar biotherapeutic products," WHO Technical Report Series No. 977, 2013</span>

<p>The clinical data on bevacizumab biosimilars specifically — not just the regulatory standards — confirm equivalence. A published comparative study found no clinically meaningful differences in pharmacokinetics, safety, or efficacy outcomes between biosimilar bevacizumab and the original Avastin in oncology patients.</p>

<span class="source-inline">Source: Pivot X et al., "Bevacizumab biosimilars in oncology: current evidence," Future Oncology, 2019 · Singh S et al., "Systematic review of bevacizumab biosimilars," Oncologist, 2020</span>

<div class="callout-amber"> <div class="callout-label">The cost difference is structural — not a sign of quality difference</div> <p>Avastin (branded bevacizumab) costs $4,000–$8,000 per cycle in the United States because it is manufactured by Genentech/Roche under intellectual property protection and sold into a healthcare system with enormous overhead costs. The biosimilar bevacizumab available in India contains the same molecule, has demonstrated pharmacokinetic equivalence, and carries the same clinical evidence base — but is manufactured by an Indian pharmaceutical company with a different cost structure. The molecule does not know which country it is in. The cancer does not know the difference. What changes is what you pay.</p> </div>

<h2 id="cost">What these drugs cost in India vs the US and UK</h2>

<p>The numbers in this table represent per-dose drug costs only — not the full treatment episode. For the complete course cost including infusion administration, monitoring, and consultations, the saving percentage is similar.</p>

<table class="cost-table"> <thead> <tr> <th>Drug / regimen</th> <th>USA (per cycle)</th> <th>UK private (per cycle)</th> <th class="india-head">India (per cycle) ✦</th> </tr> </thead> <tbody> <tr> <td>Cisplatin 40 mg/m² (weekly, concurrent)</td> <td>$400–$1,200</td> <td>£200–£600</td> <td class="saving">$30–$80 <span class="saving-pct">~94% less</span></td> </tr> <tr class="highlight"> <td>Carboplatin + paclitaxel (per 3-week cycle)</td> <td>$3,000–$8,000</td> <td>£1,500–£4,000</td> <td class="saving">$250–$700 <span class="saving-pct">~92% less</span></td> </tr> <tr> <td>Bevacizumab biosimilar (per 3-week cycle)</td> <td>$4,000–$8,000</td> <td>£2,000–£4,500</td> <td class="saving">$200–$500 <span class="saving-pct">~94% less</span></td> </tr> <tr class="highlight"> <td>Pembrolizumab (per 3-week cycle)</td> <td>$10,000–$14,000</td> <td>£5,000–£8,000</td> <td class="saving">$1,200–$2,200 <span class="saving-pct">~88% less</span></td> </tr> <tr> <td>Carboplatin + paclitaxel + bevacizumab (per cycle)</td> <td>$8,000–$16,000</td> <td>£4,000–£8,500</td> <td class="saving">$500–$1,200 <span class="saving-pct">~93% less</span></td> </tr> <tr class="highlight"> <td>Carboplatin + paclitaxel + bevacizumab + pembrolizumab (per cycle)</td> <td>$18,000–$30,000</td> <td>£9,000–£15,000</td> <td class="saving">$1,700–$3,400 <span class="saving-pct">~90% less</span></td> </tr> <tr> <td>Full 6-cycle course (carbo/pacli + bev + pembro)</td> <td>$108,000–$180,000</td> <td>£54,000–£90,000</td> <td class="saving">$10,200–$20,400 <span class="saving-pct">~90% less</span></td> </tr> </tbody> </table> <span class="source-inline">✦ India figures from GAF Healthcare hospital network pharmacy partners, 2025–2026. US: GoodRx institutional pricing and FAIR Health drug cost database, 2024. UK: private hospital published rates and NHS reference costs.</span>

<div class="stat-strip"> <div class="stat-cell"><div class="stat-label">Bevacizumab saving India vs USA</div><div class="stat-val">~94%</div></div> <div class="stat-cell"><div class="stat-label">Pembrolizumab saving India vs USA</div><div class="stat-val">~88%</div></div> <div class="stat-cell"><div class="stat-label">Cisplatin saving India vs USA</div><div class="stat-val">~94%</div></div> <div class="stat-cell"><div class="stat-label">Full quadruplet course saving</div><div class="stat-val">~90%</div></div> </div>

<h2 id="access">Why access matters — and why India solves it</h2>

<p>The survival data for bevacizumab and pembrolizumab in advanced cervical cancer is real. These drugs extend lives — not by months, but by meaningful time, with preserved quality of life in most patients. The question of who gets access to them is not abstract. It is a question about who lives longer and who does not.</p>

<p>In most of sub-Saharan Africa, bevacizumab is not on the national formulary for cervical cancer. Pembrolizumab is not available outside a handful of private hospitals in major cities — at prices that are inaccessible to the overwhelming majority of patients.</p>

<span class="source-inline">Source: Unger-Saldaña K et al., "Access to cancer treatment and diagnosis in low-income and middle-income countries," The Lancet Oncology, 2021 · UICC World Cancer Report, 2020</span>

<p>India does not just offer these drugs at lower prices. It offers them within a clinical infrastructure that can administer them correctly — with PD-L1 testing before pembrolizumab, with proper adverse event monitoring for bevacizumab, with the blood pressure management and renal protection that cisplatin requires. The drugs without the infrastructure are not enough. India provides both.</p>

<p class="impact">"I was told in Accra that the combination I needed — carboplatin, paclitaxel, bevacizumab — was simply not available. In India, I started it within two weeks of arriving. The total drug cost for six cycles was $7,000. I had budgeted three times that. The difference changed everything for my family."</p>

<div class="callout-red"> <div class="callout-label">For patients from Nigeria, Ghana, Kenya, Tanzania, Zambia, and Bangladesh</div> <p>GAF Healthcare has coordinated chemotherapy, bevacizumab, and pembrolizumab treatment in India for patients from all six countries — handling the full logistics from PD-L1 testing on arrival, through drug sourcing at partner hospital pharmacies, to discharge documentation for continuation at home between India visits. If you need these drugs and cannot access them where you are, <a href="https://gafhealthcare.in/contact" style="color:var(--red-accent);text-decoration:underline;text-decoration-color:#E8BABA;">contact us</a> and we will tell you honestly whether India can provide what you need, at a cost that is realistic for your situation.</p> </div> <span class="source-inline">Sources: IAEA Division of Human Health, Cancer Control in Africa Report, 2022 · GAF Healthcare patient outcomes database, 2024</span>

<a href="https://gafhealthcare.in/treatments/cervical-cancer-treatment" class="cta-c"> <div class="cta-arrow">→</div> <div> <div class="rl-label">Full Cervical Cancer Treatment Guide — GAF Healthcare</div> <div class="rl-desc">Surgery, chemoradiation, brachytherapy, immunotherapy, drug costs, and the complete logistics of arranging cervical cancer treatment in India from your country.</div> </div> </a>

<div class="cta-b"> <p class="cta-h">Need bevacizumab or pembrolizumab and concerned about cost or availability?</p> <p class="cta-s">Share your diagnosis, PD-L1 status if known, and existing treatment history. We will calculate the full drug cost for your specific regimen, confirm availability at our partner hospitals, and outline the logistics — at no charge, within 24 hours.</p> <a href="https://gafhealthcare.in/contact" class="btn-green">Get My Drug Cost Estimate →</a> </div>

<div class="cta-a"> <p class="cta-h">Ready to access cervical cancer treatment — including the drugs that matter — in India?</p> <p class="cta-s">Share your diagnosis, stage, and any existing treatment records. Our medical team will confirm what systemic therapy is appropriate for your case, what it costs per cycle and per course in India, and how to get started — at no charge, within 24 hours.</p> <a href="https://gafhealthcare.in/contact" class="btn-white">Start My Free Consultation →</a> </div>

<a href="https://gafhealthcare.in/treatments/cervical-cancer-treatment" class="cta-c"> <div class="cta-arrow">→</div> <div> <div class="rl-label">Full Cervical Cancer Treatment Guide — GAF Healthcare</div> <div class="rl-desc">Surgery, chemoradiation, brachytherapy, chemotherapy, immunotherapy, costs, and the complete guide to cervical cancer treatment in India for international patients.</div> </div> </a>

</div> </div> </body> </html>